Title |
CD74–NRG1 Fusions in Lung Adenocarcinoma
|
---|---|
Published in |
Cancer Discovery, April 2014
|
DOI | 10.1158/2159-8290.cd-13-0633 |
Pubmed ID | |
Authors |
Lynnette Fernandez-Cuesta, Dennis Plenker, Hirotaka Osada, Ruping Sun, Roopika Menon, Frauke Leenders, Sandra Ortiz-Cuaran, Martin Peifer, Marc Bos, Juliane Daßler, Florian Malchers, Jakob Schöttle, Wenzel Vogel, Ilona Dahmen, Mirjam Koker, Roland T. Ullrich, Gavin M. Wright, Prudence A. Russell, Zoe Wainer, Benjamin Solomon, Elisabeth Brambilla, Hélène Nagy-Mignotte, Denis Moro-Sibilot, Christian G. Brambilla, Sylvie Lantuejoul, Janine Altmüller, Christian Becker, Peter Nürnberg, Johannes M. Heuckmann, Erich Stoelben, Iver Petersen, Joachim H. Clement, Jörg Sänger, Lucia A. Muscarella, Annamaria la Torre, Vito M. Fazio, Idoya Lahortiga, Timothy Perera, Souichi Ogata, Marc Parade, Dirk Brehmer, Martin Vingron, Lukas C. Heukamp, Reinhard Buettner, Thomas Zander, Jürgen Wolf, Sven Perner, Sascha Ansén, Stefan A. Haas, Yasushi Yatabe, Roman K. Thomas |
Abstract |
We discovered a novel somatic gene fusion, CD74-NRG1, by transcriptome sequencing of 25 lung adenocarcinomas of never smokers. By screening 102 lung adenocarcinomas negative for known oncogenic alterations, we found four additional fusion-positive tumors, all of which were of the invasive mucinous subtype. Mechanistically, CD74-NRG1 leads to extracellular expression of the EGF-like domain of NRG1 III-β3, thereby providing the ligand for ERBB2-ERBB3 receptor complexes. Accordingly, ERBB2 and ERBB3 expression was high in the index case, and expression of phospho-ERBB3 was specifically found in tumors bearing the fusion (P < 0.0001). Ectopic expression of CD74-NRG1 in lung cancer cell lines expressing ERBB2 and ERBB3 activated ERBB3 and the PI3K-AKT pathway, and led to increased colony formation in soft agar. Thus, CD74-NRG1 gene fusions are activating genomic alterations in invasive mucinous adenocarcinomas and may offer a therapeutic opportunity for a lung tumor subtype with, so far, no effective treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | 57% |
Italy | 1 | 14% |
Unknown | 2 | 29% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 43% |
Scientists | 3 | 43% |
Practitioners (doctors, other healthcare professionals) | 1 | 14% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
United States | 1 | <1% |
Germany | 1 | <1% |
Unknown | 171 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 49 | 28% |
Student > Ph. D. Student | 27 | 16% |
Other | 15 | 9% |
Student > Master | 13 | 7% |
Student > Doctoral Student | 9 | 5% |
Other | 25 | 14% |
Unknown | 36 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 48 | 28% |
Biochemistry, Genetics and Molecular Biology | 39 | 22% |
Agricultural and Biological Sciences | 34 | 20% |
Chemistry | 4 | 2% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
Other | 6 | 3% |
Unknown | 40 | 23% |